List of Tables
Table 1. Global Anti-retroviral APIs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Anti-retroviral APIs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Anti-retroviral APIs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Anti-retroviral APIs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Anti-retroviral APIs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Anti-retroviral APIs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Tons)
Table 7. Global Anti-retroviral APIs Sales by Region (2020-2025) & (Tons)
Table 8. Global Anti-retroviral APIs Sales by Region (2026-2031) & (Tons)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Anti-retroviral APIs Production Growth Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Tons)
Table 11. Global Anti-retroviral APIs Production by Region (2020-2025) & (Tons)
Table 12. Global Anti-retroviral APIs Production by Region (2026-2031) & (Tons)
Table 13. Global Anti-retroviral APIs Sales by Manufacturers (2020-2025) & (Tons)
Table 14. Global Anti-retroviral APIs Sales Share by Manufacturers (2020-2025)
Table 15. Global Anti-retroviral APIs Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 16. Global Anti-retroviral APIs Revenue Market Share by Manufacturers (2020-2025)
Table 17. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 18. Global Anti-retroviral APIs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-retroviral APIs as of 2024)
Table 19. Global Anti-retroviral APIs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 20. Global Anti-retroviral APIs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Ton)
Table 21. Key Manufacturers Anti-retroviral APIs Manufacturing Base and Headquarters
Table 22. Global Anti-retroviral APIs Market Concentration Ratio (CR5 and HHI)
Table 23. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 24. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 25. Global Anti-retroviral APIs Sales by Type (2020-2025) & (Tons)
Table 26. Global Anti-retroviral APIs Sales by Type (2026-2031) & (Tons)
Table 27. Global Anti-retroviral APIs Revenue by Type (2020-2025) & (US$ Million)
Table 28. Global Anti-retroviral APIs Revenue by Type (2026-2031) & (US$ Million)
Table 29. Global Anti-retroviral APIs ASP by Type (2020-2031) & (US$/Ton)
Table 30. Technical Specifications by Key Product Type
Table 31. Global Anti-retroviral APIs Sales by Application (2020-2025) & (Tons)
Table 32. Global Anti-retroviral APIs Sales by Application (2026-2031) & (Tons)
Table 33. Anti-retroviral APIs High-Growth Sectors Demand CAGR (2024-2031)
Table 34. Global Anti-retroviral APIs Revenue by Application (2020-2025) & (US$ Million)
Table 35. Global Anti-retroviral APIs Revenue by Application (2026-2031) & (US$ Million)
Table 36. Global Anti-retroviral APIs ASP by Application (2020-2031) & (US$/Ton)
Table 37. Top Customers by Region
Table 38. Top Customers by Application
Table 39. North America Anti-retroviral APIs Growth Accelerators and Market Barriers
Table 40. North America Anti-retroviral APIs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 41. North America Anti-retroviral APIs Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 42. Europe Anti-retroviral APIs Growth Accelerators and Market Barriers
Table 43. Europe Anti-retroviral APIs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 44. Europe Anti-retroviral APIs Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 45. Asia-Pacific Anti-retroviral APIs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Asia-Pacific Anti-retroviral APIs Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 47. Asia-Pacific Anti-retroviral APIs Growth Accelerators and Market Barriers
Table 48. Southeast Asia Anti-retroviral APIs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 49. Central and South America Anti-retroviral APIs Investment Opportunities and Key Challenges
Table 50. Central and South America Anti-retroviral APIs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 51. Middle East and Africa Anti-retroviral APIs Investment Opportunities and Key Challenges
Table 52. Middle East and Africa Anti-retroviral APIs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 53. Nortec Quimica Corporation Information
Table 54. Nortec Quimica Description and Major Businesses
Table 55. Nortec Quimica Product Models, Descriptions and Specifications
Table 56. Nortec Quimica Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 57. Nortec Quimica Sales Value Proportion by Product in 2024
Table 58. Nortec Quimica Sales Value Proportion by Application in 2024
Table 59. Nortec Quimica Sales Value Proportion by Geographic Area in 2024
Table 60. Nortec Quimica Anti-retroviral APIs SWOT Analysis
Table 61. Nortec Quimica Recent Developments
Table 62. Styrax Pharma Corporation Information
Table 63. Styrax Pharma Description and Major Businesses
Table 64. Styrax Pharma Product Models, Descriptions and Specifications
Table 65. Styrax Pharma Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 66. Styrax Pharma Sales Value Proportion by Product in 2024
Table 67. Styrax Pharma Sales Value Proportion by Application in 2024
Table 68. Styrax Pharma Sales Value Proportion by Geographic Area in 2024
Table 69. Styrax Pharma Anti-retroviral APIs SWOT Analysis
Table 70. Styrax Pharma Recent Developments
Table 71. Laurus Labs Corporation Information
Table 72. Laurus Labs Description and Major Businesses
Table 73. Laurus Labs Product Models, Descriptions and Specifications
Table 74. Laurus Labs Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 75. Laurus Labs Sales Value Proportion by Product in 2024
Table 76. Laurus Labs Sales Value Proportion by Application in 2024
Table 77. Laurus Labs Sales Value Proportion by Geographic Area in 2024
Table 78. Laurus Labs Anti-retroviral APIs SWOT Analysis
Table 79. Laurus Labs Recent Developments
Table 80. Lupin Corporation Information
Table 81. Lupin Description and Major Businesses
Table 82. Lupin Product Models, Descriptions and Specifications
Table 83. Lupin Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 84. Lupin Sales Value Proportion by Product in 2024
Table 85. Lupin Sales Value Proportion by Application in 2024
Table 86. Lupin Sales Value Proportion by Geographic Area in 2024
Table 87. Lupin Anti-retroviral APIs SWOT Analysis
Table 88. Lupin Recent Developments
Table 89. Shijiazhuang Lonzeal Pharmaceuticals Corporation Information
Table 90. Shijiazhuang Lonzeal Pharmaceuticals Description and Major Businesses
Table 91. Shijiazhuang Lonzeal Pharmaceuticals Product Models, Descriptions and Specifications
Table 92. Shijiazhuang Lonzeal Pharmaceuticals Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 93. Shijiazhuang Lonzeal Pharmaceuticals Sales Value Proportion by Product in 2024
Table 94. Shijiazhuang Lonzeal Pharmaceuticals Sales Value Proportion by Application in 2024
Table 95. Shijiazhuang Lonzeal Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 96. Shijiazhuang Lonzeal Pharmaceuticals Anti-retroviral APIs SWOT Analysis
Table 97. Shijiazhuang Lonzeal Pharmaceuticals Recent Developments
Table 98. Shanghai Desano Bio-Pharmaceutical Corporation Information
Table 99. Shanghai Desano Bio-Pharmaceutical Description and Major Businesses
Table 100. Shanghai Desano Bio-Pharmaceutical Product Models, Descriptions and Specifications
Table 101. Shanghai Desano Bio-Pharmaceutical Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 102. Shanghai Desano Bio-Pharmaceutical Recent Developments
Table 103. Anhui Biochem Pharmaceutical Corporation Information
Table 104. Anhui Biochem Pharmaceutical Description and Major Businesses
Table 105. Anhui Biochem Pharmaceutical Product Models, Descriptions and Specifications
Table 106. Anhui Biochem Pharmaceutical Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 107. Anhui Biochem Pharmaceutical Recent Developments
Table 108. Fujian Cosunter Pharmaceutical Corporation Information
Table 109. Fujian Cosunter Pharmaceutical Description and Major Businesses
Table 110. Fujian Cosunter Pharmaceutical Product Models, Descriptions and Specifications
Table 111. Fujian Cosunter Pharmaceutical Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 112. Fujian Cosunter Pharmaceutical Recent Developments
Table 113. Luoxin Pharmaceuticals Corporation Information
Table 114. Luoxin Pharmaceuticals Description and Major Businesses
Table 115. Luoxin Pharmaceuticals Product Models, Descriptions and Specifications
Table 116. Luoxin Pharmaceuticals Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 117. Luoxin Pharmaceuticals Recent Developments
Table 118. Jiangsu Coben Pharmaceutical Corporation Information
Table 119. Jiangsu Coben Pharmaceutical Description and Major Businesses
Table 120. Jiangsu Coben Pharmaceutical Product Models, Descriptions and Specifications
Table 121. Jiangsu Coben Pharmaceutical Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 122. Jiangsu Coben Pharmaceutical Recent Developments
Table 123. Chongqing Carelife Pharmaceutical Corporation Information
Table 124. Chongqing Carelife Pharmaceutical Description and Major Businesses
Table 125. Chongqing Carelife Pharmaceutical Product Models, Descriptions and Specifications
Table 126. Chongqing Carelife Pharmaceutical Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 127. Chongqing Carelife Pharmaceutical Recent Developments
Table 128. Chengdu Brilliant Pharmaceutical Corporation Information
Table 129. Chengdu Brilliant Pharmaceutical Description and Major Businesses
Table 130. Chengdu Brilliant Pharmaceutical Product Models, Descriptions and Specifications
Table 131. Chengdu Brilliant Pharmaceutical Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 132. Chengdu Brilliant Pharmaceutical Recent Developments
Table 133. Fuan Pharmaceutical Corporation Information
Table 134. Fuan Pharmaceutical Description and Major Businesses
Table 135. Fuan Pharmaceutical Product Models, Descriptions and Specifications
Table 136. Fuan Pharmaceutical Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 137. Fuan Pharmaceutical Recent Developments
Table 138. Key Raw Materials Distribution
Table 139. Raw Materials Key Suppliers
Table 140. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 141. Milestones in Production Technology Evolution
Table 142. Distributors List
Table 143. Market Trends and Market Evolution
Table 144. Market Drivers and Opportunities
Table 145. Market Challenges, Risks, and Restraints
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-retroviral APIs Product Picture
Figure 2. Global Anti-retroviral APIs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Lamivudine Product Picture
Figure 4. TDF Product Picture
Figure 5. TAF Product Picture
Figure 6. Other Product Picture
Figure 7. Global Anti-retroviral APIs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Pharmaceutical
Figure 9. Scientific Research
Figure 10. Anti-retroviral APIs Report Years Considered
Figure 11. Global Anti-retroviral APIs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Anti-retroviral APIs Revenue (2020-2031) & (US$ Million)
Figure 13. Global Anti-retroviral APIs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Anti-retroviral APIs Revenue Market Share by Region (2020-2031)
Figure 15. Global Anti-retroviral APIs Sales (2020-2031) & (Tons)
Figure 16. Global Anti-retroviral APIs Sales (CAGR) by Region (2020-2031) (Tons)
Figure 17. Global Anti-retroviral APIs Sales Market Share by Region (2020-2031)
Figure 18. Global Anti-retroviral APIs Capacity, Production and Utilization (2020-2031) & (Tons)
Figure 19. Global Anti-retroviral APIs Production Trend by Region (2020-2031) (Tons)
Figure 20. Global Anti-retroviral APIs Production Market Share by Region (2020-2031)
Figure 21. Production Capacity Enablers & Constraints
Figure 22. Anti-retroviral APIs Production Growth Rate in North America (2020-2031) & (Tons)
Figure 23. Anti-retroviral APIs Production Growth Rate in Europe (2020-2031) & (Tons)
Figure 24. Anti-retroviral APIs Production Growth Rate in China (2020-2031) & (Tons)
Figure 25. Anti-retroviral APIs Production Growth Rate in Japan (2020-2031) & (Tons)
Figure 26. Top 5 and Top 10 Manufacturers Anti-retroviral APIs Sales Volume Market Share in 2024
Figure 27. Global Anti-retroviral APIs Revenue Market Share Ranking (2024)
Figure 28. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 29. Lamivudine Revenue Market Share by Manufacturer in 2024
Figure 30. TDF Revenue Market Share by Manufacturer in 2024
Figure 31. TAF Revenue Market Share by Manufacturer in 2024
Figure 32. Other Revenue Market Share by Manufacturer in 2024
Figure 33. Type Eight Revenue Market Share by Manufacturer in 2024
Figure 34. Type Nine Revenue Market Share by Manufacturer in 2024
Figure 35. Global Anti-retroviral APIs Sales Market Share by Type (2020-2031)
Figure 36. Global Anti-retroviral APIs Revenue Market Share by Type (2020-2031)
Figure 37. Global Anti-retroviral APIs Sales Market Share by Application (2020-2031)
Figure 38. Global Anti-retroviral APIs Revenue Market Share by Application (2020-2031)
Figure 39. North America Anti-retroviral APIs Sales YoY (2020-2031) & (Tons)
Figure 40. North America Anti-retroviral APIs Revenue YoY (2020-2031) & (US$ Million)
Figure 41. North America Top 5 Manufacturers Anti-retroviral APIs Sales Revenue (US$ Million) in 2024
Figure 42. North America Anti-retroviral APIs Sales Volume (Tons) by Type (2020- 2031)
Figure 43. North America Anti-retroviral APIs Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 44. North America Anti-retroviral APIs Sales Volume (Tons) by Application (2020-2031)
Figure 45. North America Anti-retroviral APIs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 46. US Anti-retroviral APIs Revenue (2020-2031) & (US$ Million)
Figure 47. Canada Anti-retroviral APIs Revenue (2020-2031) & (US$ Million)
Figure 48. Mexico Anti-retroviral APIs Revenue (2020-2031) & (US$ Million)
Figure 49. Europe Anti-retroviral APIs Sales YoY (2020-2031) & (Tons)
Figure 50. Europe Anti-retroviral APIs Revenue YoY (2020-2031) & (US$ Million)
Figure 51. Europe Top 5 Manufacturers Anti-retroviral APIs Sales Revenue (US$ Million) in 2024
Figure 52. Europe Anti-retroviral APIs Sales Volume (Tons) by Type (2020-2031)
Figure 53. Europe Anti-retroviral APIs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 54. Europe Anti-retroviral APIs Sales Volume (Tons) by Application (2020-2031)
Figure 55. Europe Anti-retroviral APIs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 56. Germany Anti-retroviral APIs Revenue (2020-2031) & (US$ Million)
Figure 57. France Anti-retroviral APIs Revenue (2020-2031) & (US$ Million)
Figure 58. U.K. Anti-retroviral APIs Revenue (2020-2031) & (US$ Million)
Figure 59. Italy Anti-retroviral APIs Revenue (2020-2031) & (US$ Million)
Figure 60. Russia Anti-retroviral APIs Revenue (2020-2031) & (US$ Million)
Figure 61. Asia-Pacific Anti-retroviral APIs Sales YoY (2020-2031) & (Tons)
Figure 62. Asia-Pacific Anti-retroviral APIs Revenue YoY (2020-2031) & (US$ Million)
Figure 63. Asia-Pacific Top 8 Manufacturers Anti-retroviral APIs Sales Revenue (US$ Million) in 2024
Figure 64. Asia-Pacific Anti-retroviral APIs Sales Volume (Tons) by Type (2020- 2031)
Figure 65. Asia-Pacific Anti-retroviral APIs Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 66. Asia-Pacific Anti-retroviral APIs Sales Volume (Tons) by Application (2020-2031)
Figure 67. Asia-Pacific Anti-retroviral APIs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 68. Indonesia Anti-retroviral APIs Revenue (2020-2031) & (US$ Million)
Figure 69. Japan Anti-retroviral APIs Revenue (2020-2031) & (US$ Million)
Figure 70. South Korea Anti-retroviral APIs Revenue (2020-2031) & (US$ Million)
Figure 71. China Taiwan Anti-retroviral APIs Revenue (2020-2031) & (US$ Million)
Figure 72. India Anti-retroviral APIs Revenue (2020-2031) & (US$ Million)
Figure 73. Central and South America Anti-retroviral APIs Sales YoY (2020-2031) & (Tons)
Figure 74. Central and South America Anti-retroviral APIs Revenue YoY (2020-2031) & (US$ Million)
Figure 75. Central and South America Top 5 Manufacturers Anti-retroviral APIs Sales Revenue (US$ Million) in 2024
Figure 76. Central and South America Anti-retroviral APIs Sales Volume (Tons) by Type (2021-2031)
Figure 77. Central and South America Anti-retroviral APIs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 78. Central and South America Anti-retroviral APIs Sales Volume (Tons) by Application (2020-2031)
Figure 79. Central and South America Anti-retroviral APIs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 80. Brazil Anti-retroviral APIs Revenue (2020-2025) & (US$ Million)
Figure 81. Argentina Anti-retroviral APIs Revenue (2020-2025) & (US$ Million)
Figure 82. Middle East, and Africa Anti-retroviral APIs Sales YoY (2020-2031) & (Tons)
Figure 83. Middle East and Africa Anti-retroviral APIs Revenue YoY (2020-2031) & (US$ Million)
Figure 84. Middle East and Africa Top 5 Manufacturers Anti-retroviral APIs Sales Revenue (US$ Million) in 2024
Figure 85. Middle East and Africa Anti-retroviral APIs Sales Volume (Tons) by Type (2021-2031)
Figure 86. South America Anti-retroviral APIs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 87. Middle East and Africa Anti-retroviral APIs Sales Volume (Tons) by Application (2020-2031)
Figure 88. Middle East and Africa Anti-retroviral APIs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 89. GCC Countries Anti-retroviral APIs Revenue (2020-2025) & (US$ Million)
Figure 90. Turkey Anti-retroviral APIs Revenue (2020-2025) & (US$ Million)
Figure 91. Egypt Anti-retroviral APIs Revenue (2020-2025) & (US$ Million)
Figure 92. South Africa Anti-retroviral APIs Revenue (2020-2025) & (US$ Million)
Figure 93. Anti-retroviral APIs Industry Chain Mapping
Figure 94. Regional Anti-retroviral APIs Manufacturing Base Distribution (%)
Figure 95. Anti-retroviral APIs Production Process
Figure 96. Regional Anti-retroviral APIs Production Cost Structure
Figure 97. Channels of Distribution (Direct Vs Distribution)
Figure 98. Bottom-up and Top-down Approaches for This Report
Figure 99. Data Triangulation
Figure 100. Key Executives Interviewed
